[Successful treatment of candida sepsis with the oral antimycotic Bay b 5097].
D058186:Acute Kidney Injury; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001555:Benzene Derivatives / Q000009:adverse effects / Q000627:therapeutic use; D001769:Blood / Q000382:microbiology; D002177:Candidiasis / Q000209:etiology / Q000628:therapy*; D003404:Creatinine / Q000097:blood; D005132:Eye Manifestations; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007964:Leukocytosis / Q000188:drug therapy; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011183:Postoperative Complications / Q000188:drug therapy; D018805:Sepsis / Q000209:etiology* / Q000628:therapy; D014508:Urea / Q000097:blood
D000935:Antifungal Agents; D001555:Benzene Derivatives; D007093:Imidazoles; D014508:Urea; D003404:Creatinine
Erfolgreiche Behandlung der Candida-Sepsis mit dem oralen Antimykotikum Bay b 5097.